GlassScriptPhysician profile
Anisa Jani
NPI 1972973923
$3,397.75
in general payments reported to CMS, 2019-2025
37 companies · $52.43 in 2025
The $52.43 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,888 · 2022: $1,006 · 2023: $373 · 2024: $78.12 · 2025: $52.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.30 | 2021-2025 | |
| Novo Nordisk INC | $471.36 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $283.06 | 2021-2022 | |
| Amgen INC. | $255.44 | 2021-2023 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $166.00 | 2021 | |
| Glaxosmithkline, LLC. | $148.19 | 2021-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $137.40 | 2022-2023 | |
| Horizon Therapeutics Plc | $123.19 | 2021 | |
| Pfizer INC. | $107.92 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.37 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $91.29 | 2021-2023 | Xarelto |
| Amarin Pharma, INC. | $68.82 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $62.33 | 2021-2023 | Contrave |
| Lilly USA, LLC | $56.35 | 2021-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $55.05 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $53.53 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.12 | 2022 | |
| Almatica Pharma LLC | $47.64 | 2022-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.54 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $35.64 | 2021 | |
| Ibsa Pharma INC. | $33.85 | 2021 | |
| Allergan, INC. | $29.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.28 | 2022 | |
| Nestle Healthcare Nutrition INC. | $27.10 | 2021 | |
| Scilex Pharmaceuticals INC. | $22.31 | 2021 | |
| Exact Sciences Corporation | $21.24 | 2023 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $19.86 | 2022 | |
| Optinose US, INC. | $18.27 | 2021 | |
| Becton, Dickinson and Company | $17.78 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.49 | 2022 | |
| Biomarin Pharmaceutical INC. | $16.03 | 2022 | |
| Eisai INC. | $15.79 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.26 | 2022 | |
| Organon LLC | $14.78 | 2022 | |
| Antares Pharma, INC. | $12.65 | 2021 | |
| Esperion Therapeutics, INC. | $12.63 | 2021 | |
| Alfasigma USA, INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anisa Jani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.